FGF2 and benign prostatic hyperplasia: As shown in Figures 4C–G, PSA, EGF, bFGF, and VEGF levels increased in the Model group but significantly reduced in all treatment groups (p < 0.01), with Finasteride and XJP-H groups exhibiting further lowering of DHT (p < 0.01), suggesting XJP's dose-dependent modulation of BPH-related serum factors.